Retapamulin Patent Expiration
Retapamulin is Used for treating impetigo caused by Staphylococcus aureus or Streptococcus pyogenes. It was first introduced by Almirall Llc
Retapamulin Patents
Given below is the list of patents protecting Retapamulin, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Altabax | US7875630 | Process salts compositions and use | Feb 14, 2027 | Almirall |
| Altabax | US8207191 | Process, salts, composition and use |
Aug 30, 2024
(Expired) | Almirall |
| Altabax | USRE39128 | Pleuromutilin derivatives as antimicrobials |
Apr 12, 2021
(Expired) | Almirall |
| Altabax | USRE43390 | Pleuromutilin derivatives as antimicrobials |
Apr 12, 2021
(Expired) | Almirall |
Retapamulin's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List